CN113491643A

CN113491643A - Antipruritic use of angiogenin

Info

Publication number: CN113491643A
Application number: CN202010201784.XA
Authority: CN
Inventors: 顾建斐; 胡坚生; 王顾莫环; 胡国富
Original assignee: Huzhou Meiyide Biotechnology Co ltd
Current assignee: Huzhou Meiyide Biotechnology Co ltd
Priority date: 2020-03-20
Filing date: 2020-03-20
Publication date: 2021-10-12
Anticipated expiration: 2040-03-20
Also published as: CN113491643B

Abstract

The invention provides an application of angiogenin in relieving itching, in particular to an itching relieving product containing angiogenin, which can effectively relieve itching, has quick response and almost has no side effect; but also can effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch or skin itch caused by excessive irradiation of sunlight or ultraviolet light; in addition, the itching relieving product has the function of relieving itching, has the effects of resisting wrinkles and fading spots, and is particularly suitable for people with sensitive skin.

Description

Antipruritic use of angiogenin

Technical Field

The invention relates to the field of cosmetics, in particular to an anti-itching application of angiogenin and an anti-itching product containing the angiogenin.

Background

Under normal conditions, due to the water absorption effect and the barrier function of the stratum corneum and the covering effect of lipid substances secreted by sweat glands and sebaceous glands, water is not easy to lose, the stratum corneum can keep a certain water content, the water of the stratum corneum is increased and kept, and the skin can keep soft and keep elasticity. There are two main reasons for causing the stratum corneum to lack water and thus causing the skin to dry: firstly, the climate is dry and the relative humidity is low; secondly, the normal water absorption and barrier function of the skin are impaired.

Dietary, environmental, etc., can cause skin itch, especially in some individuals with sensitive skin. In modern society, some people who use cosmetics often induce skin irritation, inflammation, allergy and itching due to the use of cosmetics.

The current treatment or alleviation of pruritus mainly comprises: antihistamines and antiallergic agents for oral administration, and antihistamines, adrenocortical steroids, non-steroidal anti-inflammatory agents for external use. However, when the oral preparation is used, problems such as a certain period of time required for clinical effects, side effects (sleepiness and lassitude) on the central nervous system, and damage to the digestive system may occur. On the other hand, when the external preparation is used, the antipruritic effect is insufficient, and particularly when the steroid preparation is used for a long period of time, there are side effects such as decrease in adrenal function and steroid acne.

Therefore, the development of an antipruritic product which is safe to use, has small side effect and is quick and effective is urgently needed in the field.

Disclosure of Invention

The invention aims to provide an antipruritic product which is safe to use, small in side effect, quick and effective and application thereof in relieving itching. The anti-itch product of the present invention contains angiogenin as an anti-itch ingredient.

The invention provides an application of angiogenin in preparing an antipruritic product.

In another preferred embodiment, the anti-itch product is a cosmetic composition.

In another preferred embodiment, the anti-itch product is further used for one or more purposes selected from the group consisting of: resisting wrinkle, removing speckle, and whitening skin.

In another preferred embodiment, the effective concentration of angiogenin is from 0.000001% to 0.1% of the total weight.

In another preferred embodiment, the effective concentration of angiogenin is from 0.000001% to 0.001% of the total weight.

In another preferred embodiment, the effective concentration of angiogenin is 0.000001% to 0.00001% of the total weight.

In another preferred embodiment, the anti-itch product is used to inhibit or relieve skin itch.

In another preferred embodiment, the pruritus comprises skin pruritus caused by a factor selected from the group consisting of: allergic skin itch, general skin itch, eczematous itch, or a combination thereof.

In another preferred embodiment, the general type of skin itch includes itch caused by dry skin.

In another preferred embodiment, the pruritus comprises systemic pruritus and localized pruritus.

In another preferred embodiment, the skin itch occurs at a site selected from the group consisting of: face, neck, back, chest, abdomen, limbs, waist, or combinations thereof.

In another preferred embodiment, the skin itch is allergic skin itch.

In another preferred embodiment, the skin itch is allergic skin itch that is not accompanied by inflammation and/or redness.

In another preferred embodiment, the skin pruritus is allergic skin pruritus accompanied by inflammation and/or red swelling.

In another preferred embodiment, the skin pruritus is allergic skin pruritus accompanied by inflammation and/or red swelling and occurring on face or neck.

In another preferred example, the skin itch is skin itch caused by sunlight or ultraviolet light (UV) irradiation.

In another preferred embodiment, the anti-itch product is suitable for use by people with sensitive skin.

In another preferred embodiment, the skin sensitivity is dry, red, blotchy, red, flaky, or pimpled skin surface.

In another preferred embodiment, the angiogenin is human angiogenin.

In another preferred embodiment, the human angiogenin is recombinant human angiogenin.

In another preferred embodiment, the N-terminal of the recombinant human angiogenin is methionine, and the sequence of the recombinant human angiogenin is shown as SEQ ID NO:2, respectively.

In another preferred embodiment, the angiogenin is prepared by:

(a) culturing a host cell under conditions suitable for expression of angiogenin, whereby angiogenin is expressed, wherein the host cell comprises a vector for expression of angiogenin, the vector comprising a DNA sequence encoding angiogenin; and (b) isolating and purifying the angiogenin expressed in step (a).

In another preferred example, the anti-itch product is a liquid composition, a paste composition, a gel composition, or a spray.

In another preferred embodiment, the anti-itch product is selected from the group consisting of: cream, milky lotion, cream, sunscreen cream, facial mask, toner, eye cream, massage cream, and hand cream.

In another preferred embodiment, the formula of the itching relieving product is cream or facial mask.

In another preferred embodiment, the anti-itch product (or anti-itch composition) does not contain skin-irritating components.

In another preferred embodiment, the irritating component is selected from the group consisting of: alcohol, hormone, tartaric acid, phenoxyethanol and heavy metal.

In another preferred embodiment, the anti-itch product further comprises a material selected from the group consisting of: an ultraviolet light absorber, an ultraviolet light scattering agent, a toner, or a mixture thereof.

In another preferred embodiment, the anti-itch product comprises additional ingredients selected from the group consisting of: water, glycerol, yeast extract, Hamamelis virginiana (HAMAMELIS VIRGINIANA) extract, Cucumis SATIVUS (Cucumis SATIVUS) fruit extract, Matricaria CHAMOMILLA (Chamomilla RECUTITA) flower extract, Fucus VESICULOSUS (Fucus VESICULOSUS) extract, Paeonia lactiflora (Paeonia ALBIFLORA) root extract, sodium hyaluronate, and xanthan gum.

In another preferred embodiment, the anti-itch product is applied directly to or around the itchy areas of the skin.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.

Drawings

Fig. 1 is a graph of the effect of a patient's nail with intractable itching of unknown cause in the lower back before, after one week of continuous application and after 2 weeks of continuous application of a skin cream comprising reconstituted ANG.

Figure 2 is a graph of the effect of patient b on red, swollen and itchy face before and after 3 consecutive days of application of a skin cream comprising reconstituted ANG.

Detailed Description

The present inventors have made extensive and intensive studies and, for the first time, have unexpectedly found that angiogenin has an antipruritic function, and when an effective amount of angiogenin is applied to or around the itchy site of the skin, not only can effective antipruritic effect be achieved, but also the effect is fast and there is hardly any side effect. Experiments show that the angiogenin can not only inhibit, relieve and eliminate skin itch, but also effectively improve symptoms of skin redness and swelling, inflammation and the like at or around the itch part. On the basis of this, the present invention has been completed.

Specifically, the itching relieving product of the invention can not only inhibit, relieve and eliminate common skin itch, but also effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch (such as cosmetic allergic skin itch), skin itch caused by excessive irradiation of sunlight or ultraviolet light. In addition, the itching relieving product can effectively treat and relieve skin pruritus and can also effectively improve skin problems such as skin aging, pigmentation and the like.

Angiogenin

As used herein, "angiogenin," "polypeptide ANG protein," and "ANG" are used interchangeably to refer to angiogenin from a mammal, including wild-type and mutant angiogenin. The preferred angiogenin is human angiogenin. The term includes human angiogenin produced recombinantly or non-recombinantly, preferably ANG produced by recombinant means.

In the present invention, the active ingredient for relieving itching is angiogenin, preferably human angiogenin, more preferably recombinantly produced human angiogenin.

Human Angiogenin (Angiogenin) is a protein consisting of 123 amino acids, the N-terminal of the recombinant human Angiogenin is additionally provided with a methionine consisting of 124 amino acids, and the amino acid sequence of the recombinant human Angiogenin is SEQ ID NO:2:

MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP。

human angiogenin is a secreted, water-soluble protein with an isoelectric point greater than 10. Angiogenin is present in normal human blood, typically in an amount of 250-360 ng/ml.

The main physiological function of angiogenin is to stimulate angiogenesis under specific conditions and maintain the normal function of blood vessels in the body. Since metabolism of various organs and tissues in the body requires blood circulation to deliver oxygen and nutrients, and to remove waste gases and waste materials, angiogenin plays an important role in maintaining normal physiological functions of various tissues and organs in the body.

In addition to the main effects of stimulating angiogenesis, angiogenin inhibits melanogenesis secreted by melanophore (Melanocyte) on the skin surface, thereby providing anti-wrinkle and whitening effects. Meanwhile, angiogenin can promote melanoblasts, Fibroblasts (fibroplasts), Keratinocytes (keratincs) and epidermal Cells (epidermal Cells) to secrete Collagen (Collagen) and Elastin (Elastin), so that the effects of preventing skin aging and increasing skin elasticity are achieved.

Angiogenin is present in milk in addition to normal human blood. Human angiogenin can be isolated from human plasma or from human tumor cell culture supernatant. Bovine angiogenin can be isolated from milk. Human angiogenin can also be prepared by genetic engineering methods. Compared with the angiogenin naturally generated in human body, the human angiogenin prepared by the genetic engineering method has the same physicochemical property and biological activity.

Preparation of angiogenin

In the present invention, angiogenin is preferably produced by recombinant means. A preferred method comprises the steps of:

(a) culturing a host cell under conditions suitable for expression of angiogenin, whereby angiogenin is expressed, wherein the host cell comprises a vector for expression of angiogenin, the vector comprising the amino acid sequence of SEQ ID NO:1, SEQ ID NO:1: atgcaggataactccaggtacacacacttcctgacccagcactatgatgccaaaccacagggccgggatgacagatactgtgaaagcatcatgaggagacggggcctgacctcaccctgcaaagacatcaacacatttattcatggcaacaagcgcagcatcaaggccatctgtgaaaacaagaatggaaaccctcacagagaaaacctaagaataagcaagtcttctttccaggtcaccacttgcaagctacatggaggttccccctggcctccatgccagtaccgagccacagcggggttcagaaacgttgttgttgcttgtgaaaatggcttacctgtccacttggatcagtcaattttccgtcgtccg.

(b) Isolating and purifying the angiogenin expressed in step (a).

In a preferred embodiment, the angiogenin-encoding DNA molecule is engineered according to the codon preference of the host cell of choice. A specific coding sequence is shown as SEQ ID NO:1 is shown.

Antipruritic product

The effective component of the antipruritic product of the invention is angiogenin, preferably human angiogenin, more preferably recombinantly produced human angiogenin. Generally, in the antipruritic products of the present invention, the effective concentration of angiogenin is 0.000001% to 0.1% or more by weight of the total. Of course, the concentration of angiogenin can also be higher than 0.1% because this still has an antipruritic effect. From the viewpoint of production cost, the effective concentration of angiogenin is preferably 0.000001% to 0.001%, more preferably 0.000001% to 0.0001%, and most preferably 0.000001% to 0.00001% by weight of the total.

Angiogenin for use in the invention may be in native or recombinant form, preferably recombinant form. Angiogenin for use in the invention is preferably purified, for example angiogenin with a purity of greater than 80%, preferably greater than 90%, more preferably greater than 95%, most preferably greater than 99%.

In the anti-itch product of the present invention, in addition to angiogenin as a main active ingredient, other ingredients known in the art, such as arbutin (Albutin), kojic acid, hydrogenated casein, bovine angiogenin, or a mixture thereof, may be contained.

In addition, the anti-itch product of the present invention may also include additives commonly used in the art, such as fragrances, essential oils, stabilizers, moisturizers, vitamins, essential fatty acids, lipophilic sunscreens, liposoluble polymers, and the like. Of course, the skilled person will be careful to select the optional additive compounds and/or their amounts such that the advantageous properties of the angiogenin of the invention are not, or are not substantially, impaired by these additives.

The anti-itch product of the present invention may be formulated into various formulations commonly used in the art, such as creams, lotions, creams, face lotions, sun screens, face masks, lotions, eye creams, massage creams, hand creams, or other cosmetics for the face, neck, hands, and body.

The antipruritic product of the invention can be directly applied to the skin or applied to the skin.

The invention has the main advantages that:

1. angiogenin can inhibit, relieve and eliminate skin itch very quickly, and has no side effect;

2. the angiogenin can not only inhibit, relieve and eliminate common skin itch, but also effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch or skin itch caused by excessive irradiation of sunlight or ultraviolet light;

3. the itching relieving product disclosed by the invention not only has a function of relieving itching, but also has the effects of resisting wrinkles and fading spots, and is particularly suitable for people with sensitive skin.

The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.

Example 1 Rapid antipruritic Effect of ANG

Subject: 20 volunteers with mild itching or moderate itching (no redness), 12 men and 8 women aged 40 to 60 years were randomly divided into 2 groups, and the number of men and women was the same in the experimental group and the control group.

20 volunteers had skin pruritus due to allergy, dryness and unknown reasons, and the skin pruritus sites included: face, neck, back, waist, legs, arms. The causes of pruritus were not differentiated at the time of grouping.

All volunteers had no other systemic disease and had not taken antibiotics and immunosuppressants within the last month.

When selecting volunteers, the skin itch degree of each volunteer candidate was distinguished according to the subjectively judged degrees of four-level itch (no itch, mild itch, moderate itch, and severe itch) of the volunteer candidate, and a total of 20 volunteer candidates having the skin itch degrees of mild itch and moderate itch were selected as test subjects of the present embodiment.

The test subjects did not use topical steroids for the week before the start of the experiment, which limited the use of topical steroids during the experiment and also had to use other antipruritic substances.

For the test group, a skin cream containing recombinant human angiogenin (0.00001% of the total weight of recombinant human angiogenin) was applied once to or around the itchy site of the skin.

For the control group, a skin cream containing no recombinant human angiogenin and the same ingredients as the rest was applied once to the itchy site of the skin or its surroundings.

Skin itch was scored according to table 1 for the degree of itch 5 minutes prior to application, and was still mild or moderate.

30 minutes after application, the skin itch was scored again by each volunteer according to Table 2.

TABLE 1 itch degree division Table

Degree of itching	Standard of merit
		Without pruritus	Subjective feeling without any skin itch
Mild itching	The subjective feeling of slight skin itching
		Moderate pruritus	The subjective feeling is that the skin is itchy and the skin is itchy to endure
Severe pruritus	The skin itch is subjectively felt and is hard to endure

TABLE 2 evaluation chart of degree of pruritus improvement

The statistical results are shown in table 3 below:

TABLE 3

Control group	Test set
		4 fen x 0 (human)	4 fen x 5 (human)
3 fen x 0 (human)	3 fen x 2 (human)
		2 fen x 3 (human)	2 fen x 2 (human)
1 fen x 7 (human)	1 fen x 1 (human)
		Total score of 13 points	Total score of 31

The test results showed that ANG rapidly and significantly suppressed and alleviated skin itch in the test group to 70% of the test subjects without itch, compared to the control group.

Example 2ANG has a remarkable antipruritic effect on pruritus accompanied by red swelling

Subject: 10 volunteers with red and swollen pruritus, 2 males and 8 females, aged from 20 to 45 years, were randomly divided into 2 groups, and the number of males and females in the experimental group and the control group was the same.

The red and swollen parts of 10 volunteers all included: face or neck.

When selecting volunteers, the degree of skin itch of each volunteer candidate was distinguished according to the subjectively judged degree of four-level itch (no itch, mild itch, moderate itch, and severe itch) of the volunteer candidate. Meanwhile, the face or neck red swelling area of the candidate volunteer subject is divided into four grades (no red swelling, mild red swelling, moderate red swelling and severe red swelling), and 10 candidate volunteer subjects with mild pruritus degree and moderate pruritus degree and mild red swelling degree and moderate red swelling degree are selected as test subjects.

For the test group, a skin care product (skin cream, containing recombinant human angiogenin in an amount of 0.00005% by weight) containing recombinant human angiogenin was applied to or around the inflamed part of the skin twice a day, once in the morning and evening, for a total of 3 days.

For the control group, a skin care product containing no recombinant human angiogenin and the same remaining ingredients was applied to the skin twice a day, once in the morning and once in the evening, for a total of 3 days, at or around the site of red and swollen itch.

Before application, skin itching was scored by the volunteer according to the degree of itching given in table 1 (example 1), and statistics were included for mild itching or moderate itching. Meanwhile, each volunteer scored the degree of redness of skin according to Table 4, and was counted for mild redness or moderate redness.

After 3 days of application, the redness and itching of the skin were again scored by each volunteer according to table 5.

TABLE 4 grading table of degree of redness and swelling

TABLE 5 evaluation chart of degree of improvement of redness and swelling and itching

The statistical results are shown in table 6 below:

TABLE 6

The test results showed that for skin itching accompanied by redness, ANG not only significantly suppressed and alleviated skin itching but also significantly eliminated redness of skin at or around the itching site in the test group to which ANG was applied, as compared with the control group, and that 80% of the test subjects (4/5) had a significant effect of skin itching.

Example 3 antipruritic effect of ANG on cutaneous pruritus caused by solar or Ultraviolet (UV) light irradiation

Subject: the degree of itching was scored according to Table 1 for skin itching, and 4 skin itching volunteers who were exposed to sunlight (seaside) for 1 hour and were in moderate itching, 2 men and 2 women were included and randomly divided into 2 groups, and the number of men and women was the same in the experimental group and the control group.

Sites of skin itch include: face, neck and back.

For the test group, a skin cream containing recombinant human angiogenin (0.00001% of the total weight of recombinant human angiogenin) was applied to the face, neck and back 2 times a day for a total of 2 days.

For the control group, a skin cream containing no recombinant human angiogenin and the same other ingredients was applied to the itchy face, neck and back 2 times a day for a total of 2 days.

After 2 days of application, the skin itching was again scored by each volunteer according to table 2.

The statistical results are shown in table 7 below:

TABLE 7

Control group	Test set
		4 fen x 0 (human)	4 fen x 1 (human)
3 fen x 0 (human)	3 fen x 1 (human)
		2 fen x 1 (human)	2 fen x 0 (human)
1 fen x 1 (human)	1 fen x 0 (human)
		Total score of 3 points	Total score of 7 points

The test results showed that ANG significantly suppressed and alleviated skin itch caused by excessive irradiation of sunlight or ultraviolet light (UV) in the test group to which ANG was applied, compared to the control group.

Example 4 antipruritic product containing angiogenin (ANG skin cream)

In this example, the itch-relieving component in the formulation of ANG skin cream is ANG polypeptide (recombinant human angiogenin), and its content is 0.00001% of the total weight of the skin cream. The ANG skin cream comprises the following other components: polyacryl dimethyl taurine, hydrogenated polydecene and trideceth-yl alcohol, olive oil cetyl ester and sorbitan olive oil oleate, glyceryl stearate/polyethylene glycol stearate, cetearyl alcohol, caprylic/capric triglyceride, isohexadecane, alpha-tocopheryl acetate, propylene glycol, hydroxyacetone, phenoxyethanol/ethylhexyl glycerol, chlorphenesin/1, 3 butanediol, carrageenan extract, phenoxyethanol, glycosyl trehalose and water (in appropriate amounts).

Example 5 antipruritic product containing angiogenin (Biofiber ANG mask)

In this embodiment, a bio-fiber ANG mask (including a mask patch and essence) is prepared, wherein the essence itching-stopping component is ANG polypeptide (recombinant human angiogenin) in an amount of 0.00001% of the total weight of the skin cream. The biological fiber ANG facial mask essence comprises the following other components: water (in appropriate amount), butylene glycol, glycerol, propylene glycol, yeast extract, betaine, hamamelis virginiana (HAMAMELIS VIRGINIANA) extract, Cucumis SATIVUS (Cucumis SATIVUS) fruit extract, Matricaria CHAMOMILLA flower extract, Fucus VESICULOSUS (Fucus VESICULOSUS) extract, beta-glucan, trehalose, dipropylene glycol, p-hydroxyacetophenone, sodium hyaluronate, Sclerotinia sclerotiorum (SCLETUSSII) gum, xanthan gum, caprylyl glycol, dipotassium glycyrrhizinate, and disodium EDTA.

The antipruritic product is prepared according to the conventional conditions in the field.

Example 6 antipruritic effect of ANG on itching in patients with unknown causes (case one)

The patients: jia Yi (woman) age 55

Symptoms are: intractable pruritus of unknown waist and back reasons

And (3) itching relieving treatment: ANG cream (example 4) was applied to the site of itching and the effect was observed

An appropriate amount of ANG skin cream is lightly applied to the itching part and the periphery of the waist and the back, and after 10 minutes, the itching feeling disappears. On day 2, itching reappeared but was reduced from that before the first application of the ANG containing cream, and the ANG cream was continued to be applied and after 10 minutes the itching disappeared. The application is continued for 1 week, 1-2 times per day, and the patient is substantially healed; the application was continued for 2 weeks and the recovery was complete.

The results of comparing the itching sites before and after application of the skin cream containing recombinant ANG in this case are shown in fig. 1.

Example 6ANG antipruritic effect on facial redness and itching patients (case two)

The patients: "Yizhi" (female) age 35

Symptoms are: red swelling and itching of face

And (3) itching relieving treatment: ANG cream (example 4) was applied to the site of itching and the effect was observed.

The patients were substantially healed by lightly applying an appropriate amount of ANG cream to the inflamed area of the face and around the inflamed area, once a day, morning and evening, for 3 consecutive days, and the results of comparing the inflamed and itchy area before and after application of the cream containing recombinant ANG are shown in fig. 2.

All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Sequence listing

<110> Huzhou Meiyi Biotechnology Ltd

<120> antipruritic use of angiogenin

<130> P2019-1702

<160> 2

<170> SIPOSequenceListing 1.0

<210> 1

<211> 372

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 1

atgcaggata actccaggta cacacacttc ctgacccagc actatgatgc caaaccacag 60

ggccgggatg acagatactg tgaaagcatc atgaggagac ggggcctgac ctcaccctgc 120

aaagacatca acacatttat tcatggcaac aagcgcagca tcaaggccat ctgtgaaaac 180

aagaatggaa accctcacag agaaaaccta agaataagca agtcttcttt ccaggtcacc 240

acttgcaagc tacatggagg ttccccctgg cctccatgcc agtaccgagc cacagcgggg 300

ttcagaaacg ttgttgttgc ttgtgaaaat ggcttacctg tccacttgga tcagtcaatt 360

ttccgtcgtc cg 372

<210> 2

<211> 124

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 2

Met Gln Asp Asn Ser Arg Tyr Thr His Phe Leu Thr Gln His Tyr Asp

1 5 10 15

Ala Lys Pro Gln Gly Arg Asp Asp Arg Tyr Cys Glu Ser Ile Met Arg

20 25 30

Arg Arg Gly Leu Thr Ser Pro Cys Lys Asp Ile Asn Thr Phe Ile His

35 40 45

Gly Asn Lys Arg Ser Ile Lys Ala Ile Cys Glu Asn Lys Asn Gly Asn

50 55 60

Pro His Arg Glu Asn Leu Arg Ile Ser Lys Ser Ser Phe Gln Val Thr

65 70 75 80

Thr Cys Lys Leu His Gly Gly Ser Pro Trp Pro Pro Cys Gln Tyr Arg

85 90 95

Ala Thr Ala Gly Phe Arg Asn Val Val Val Ala Cys Glu Asn Gly Leu

100 105 110

Pro Val His Leu Asp Gln Ser Ile Phe Arg Arg Pro

115 120

Claims

1. Use of angiogenin for the preparation of an anti-itch product.

2. The use of claim 1, wherein the anti-itch product is further used for one or more purposes selected from the group consisting of: resisting wrinkle, removing speckle, and whitening skin.

3. The use according to claim 1, wherein the effective concentration of angiogenin is from 0.000001% to 0.1% of the total weight.

4. The use of claim 1, wherein the pruritus comprises skin pruritus caused by factors selected from the group consisting of: allergic skin itch, general skin itch, eczematous itch, or a combination thereof.

5. The use according to claim 1, wherein the cutaneous pruritus occurs at a site selected from the group consisting of: face, neck, back, chest, abdomen, limbs, waist, or combinations thereof.

6. Use according to claim 1, characterized in that the cutaneous pruritus is an allergic cutaneous pruritus accompanied by inflammation and/or redness and occurring on the face or neck.

7. The use according to claim 1, wherein the skin itch is skin itch caused by sunlight or Ultraviolet (UV) light irradiation.

8. The use of claim 1, wherein the angiogenin is human angiogenin.

9. The use according to claim 1, wherein the anti-itch product is a liquid composition, a paste composition, a gel composition, or a spray.

10. The use according to claim 1, wherein the anti-itch product is selected from the group consisting of: cream, milky lotion, cream, sunscreen cream, facial mask, toner, eye cream, massage cream, and hand cream.